Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 203
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Int J Immunopathol Pharmacol ; 35: 20587384211038098, 2021.
Article in English | MEDLINE | ID: mdl-34939873

ABSTRACT

OBJECTIVE: This study aims to dissect the mechanism of traditional Chinese medicinal herbs against asthma; we chose to first focus on the main chemical components of licorice to investigate their contribution to asthmatic inflammation inhibition. METHODS: Production of cellular nucleotide molecules such as cAMP, cGMP, and cGAMP was examined by using enzyme-linked immunosorbent assay (ELISA). Enzyme-encoding genes were tested in vitro using quantitative real-time PCR and protein level was detected by Western blotting analysis. In addition, co-culturing of murine dendritic cells together with T cells was conducted to examine the expression of cytokine genes and host immune response. RESULTS: We found that one of the components within licorice, named liquiritigenin (LR), could efficiently enhance cAMP production in different cell lines. The augmentation of such molecules was linked to the high expression of cAMP synthesis genes and repressed expression of cAMP breaking down genes. In addition, the downstream immune response was also alleviated by the increase in cAMP levels by LR, suggesting the great potential of this molecule against inflammation. Subsequent immunological tests showed that LR could efficiently inhibit the expression of several cytokines and alter the NF-κB pathway and T cell polarization. CONCLUSION: Altogether, we have identified a promising antiasthmatic agent LR that could exhibit immunosuppressive function by elevating the cAMP level.


Subject(s)
Asthma , Cyclic AMP/biosynthesis , Dendritic Cells/immunology , Flavanones/pharmacology , Pterygota , Signal Transduction/drug effects , Anti-Asthmatic Agents/pharmacology , Asthma/drug therapy , Asthma/immunology , Asthma/pathology , Cells, Cultured , Cytokines/metabolism , Drugs, Chinese Herbal/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Humans , Immunity, Cellular/drug effects , Immunity, Cellular/genetics , Immunologic Tests/methods , NF-kappa B/metabolism
2.
Neurochem Int ; 145: 104983, 2021 05.
Article in English | MEDLINE | ID: mdl-33577869

ABSTRACT

Improvements in neuronal plasticity are considered to be conducive to recovery from neuropathic pain. Electroacupuncture (EA) is regarded as an effective rehabilitation method for neuropathic pain. However, the effects and potential mechanism associated with EA-induced repair of hyperesthesia are not fully understood. Evidence has suggested that the adenosine A2A receptor (A2AR) and the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway play an important role in improving neuropathic pain. Here, we examined the function of EA in promoting neuronal plasticity in spinal nerve ligation (SNL) rats. The A2AR antagonist SCH58261, A2AR agonist 2-p-(2-carboxyethyl)phenethylamino-50-N-ethylcarboxamido adenosine HCl (CGS21680) and A2AR siRNA were used to confirm the relationship between A2AR and the cAMP/PKA pathway as well as the effects of A2AR on EA-induced improvements in neurobehavioral state and neuronal plasticity. Mechanical withdrawal threshold (MWT), thermal withdrawal latency (TWL), HE staining, Western blotting, RT-PCR, immunofluorescence, enzyme-linked immunosorbent assay, Nissl staining, silver staining, Golgi-Cox staining and transmission electron microscopy were used to evaluate the changes in neurobehavioral performance, protein expression, neuronal structure and dendrites/synapses. The results showed that EA and CGS21680 improved the behavioral performance, neuronal structure and dendritic/synaptic morphology of SNL rats, consistent with higher expression levels of A2AR, cAMP and PKA. In contrast to the positive effects of EA, SCH58261 inhibited dendritic growth and promoted dendritic spine/synaptic remodeling. In addition, the EA-induced improvement in neuronal plasticity was inhibited by SCH58261 and A2AR siRNA, consistent with lower expression levels of A2AR, cAMP and PKA, and worse behavioral performance. These results indicate that EA suppresses SNL-induced neuropathic pain by improving neuronal plasticity via upregulating the A2AR/cAMP/PKA signaling pathway.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/biosynthesis , Cyclic AMP/biosynthesis , Electroacupuncture/methods , Neuralgia/metabolism , Neuronal Plasticity/physiology , Receptor, Adenosine A2A/biosynthesis , Adenosine A2 Receptor Agonists/pharmacology , Adenosine A2 Receptor Antagonists/pharmacology , Animals , Ligation/adverse effects , Male , Neuralgia/therapy , Neuronal Plasticity/drug effects , Pain Measurement/methods , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Signal Transduction/physiology , Spinal Nerves/injuries
3.
Mol Neurobiol ; 55(7): 6037-6049, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29143287

ABSTRACT

Lipoic acid (LA) exhibits antioxidant and anti-inflammatory properties; supplementation reduces disease severity and T lymphocyte migration into the central nervous system in a murine model of multiple sclerosis (MS), and administration in secondary progressive MS (SPMS) subjects reduces brain atrophy compared to placebo. The mechanism of action (MOA) of LA's efficacy in suppression of MS pathology is incompletely understood. LA stimulates production of the immunomodulator cyclic AMP (cAMP) in vitro. To determine whether cAMP could be involved in the MOA of LA in vivo, we performed a clinical trial to examine whether LA stimulates cAMP production in healthy control and MS subjects, and whether there are differences in the bioavailability of LA between groups. We administered 1200 mg of oral LA to healthy control, relapsing remitting MS (RRMS) and SPMS subjects, and measured plasma LA and cAMP levels in peripheral blood mononuclear cells (PBMCs). There were no significant differences between the groups in pharmacokinetic (PK) parameters. Healthy and SPMS subjects had increased cAMP at 2 and 4 h post-LA treatment compared to baseline, while RRMS subjects showed decreases in cAMP. Additionally, plasma concentrations of prostaglandin E2 (PGE2, a known cAMP stimulator) were significantly lower in female RRMS subjects compared to female HC and SPMS subjects 4 h after LA ingestion. These data indicate that cAMP could be part of the MOA of LA in SPMS, and that there is a divergent response to LA in RRMS subjects that may have implications in the efficacy of immunomodulatory drugs. This clinical trial, "Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis," NCT00997438, is registered at https://clinicaltrials.gov/ct2/show/record/NCT00997438 .


Subject(s)
Cyclic AMP/biosynthesis , Multiple Sclerosis, Chronic Progressive/drug therapy , Multiple Sclerosis, Chronic Progressive/metabolism , Thioctic Acid/therapeutic use , Administration, Oral , Adult , Aged , Dinoprostone/blood , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Models, Biological , Multiple Sclerosis, Chronic Progressive/blood , Multiple Sclerosis, Chronic Progressive/pathology , Serum Albumin/metabolism , Thioctic Acid/blood , Thioctic Acid/pharmacokinetics , Thioctic Acid/pharmacology , Tumor Necrosis Factor-alpha/blood
4.
Gen Comp Endocrinol ; 250: 152-161, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28636888

ABSTRACT

The neuropeptide galanin (Gal) is a putative factor regulating puberty onset and reproduction through its actions on the pituitary. The present study investigated the pituitary responsiveness to galanin and the patterns of galanin receptors (Galrs) expression throughout the reproductive cycle of two years old male European sea bass (Dicentrarchus labrax), an important aquaculture species. Quantitative analysis of pituitary and hypothalamus transcript expression of four galr subtypes revealed differential regulation according to the testicular developmental stage, with an overall decrease in expression from the immature stage to the mid-recrudescence stage. Incubation of pituitary cells with mammalian 1-29Gal peptide induced significant changes in cAMP concentration, with sensitivities that varied according to the testicular development stages. Furthermore 1-29Gal was able to stimulate both follicle stimulating hormone (Fsh) and luteinizing hormone (Lh) release from pituitary cell suspensions. The magnitude of the effects and effective concentrations varied according to reproductive stage, with generalized induction of Fsh and Lh release in animals sampled in January (full spermiation). The differential expression of galrs in pituitary and hypothalamus across the reproductive season, together with the differential effects of Gal on gonadotropins release in vitro strongly suggests the involvement of the galaninergic system in the regulation the hypothalamus-pituitary-gonad axis of male sea bass. This is to our knowledge the first clear evidence for the involvement of galanin in the regulation of reproduction in non-mammalian vertebrates.


Subject(s)
Bass/physiology , Galanin/pharmacology , Pituitary Gland/metabolism , Reproduction/drug effects , Animals , Bass/genetics , Colforsin/pharmacology , Cyclic AMP/biosynthesis , Follicle Stimulating Hormone/metabolism , Gametogenesis/drug effects , Gene Expression Profiling , Gonadotropins/pharmacology , Hypothalamus/drug effects , Hypothalamus/metabolism , Luteinizing Hormone/metabolism , Male , Pituitary Gland/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Galanin/genetics , Receptors, Galanin/metabolism , Reproduction/physiology
5.
Neural Plast ; 2016: 5320641, 2016.
Article in English | MEDLINE | ID: mdl-28090359

ABSTRACT

Pain memory is considered as endopathic factor underlying stubborn chronic pain. Our previous study demonstrated that electroacupuncture (EA) can alleviate retrieval of pain memory. This study was designed to observe the different effects between EA and indomethacin (a kind of nonsteroid anti-inflammatory drugs, NSAIDs) in a rat pain memory model. To explore the critical role of protein kinase A (PKA) in pain memory, a PKA inhibitor was microinjected into anterior cingulate cortex (ACC) in model rats. We further investigated the roles of the cyclic adenosine monophosphate (cAMP), PKA, cAMP response element-binding protein (CREB), and cAMP/PKA/CREB pathway in pain memory to explore the potential molecular mechanism. The results showed that EA alleviates the retrieval of pain memory while indomethacin failed. Intra-ACC microinjection of a PKA inhibitor blocked the occurrence of pain memory. EA reduced the activation of cAMP, PKA, and CREB and the coexpression levels of cAMP/PKA and PKA/CREB in the ACC of pain memory model rats, but indomethacin failed. The present findings identified a critical role of PKA in ACC in retrieval of pain memory. We propose that the proper mechanism of EA on pain memory is possibly due to the partial inhibition of cAMP/PKA/CREB signaling pathway by EA.


Subject(s)
Cyclic AMP Response Element-Binding Protein/biosynthesis , Cyclic AMP-Dependent Protein Kinases/biosynthesis , Cyclic AMP/biosynthesis , Electroacupuncture/methods , Gyrus Cinguli/metabolism , Pain/metabolism , Analgesia/methods , Animals , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Disease Models, Animal , Gyrus Cinguli/drug effects , Indomethacin/administration & dosage , Injections, Intraventricular , Male , Memory/drug effects , Memory/physiology , Pain/drug therapy , Pain Measurement/drug effects , Pain Measurement/methods , Protein Kinase Inhibitors/administration & dosage , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Signal Transduction/physiology , Treatment Outcome
6.
Domest Anim Endocrinol ; 54: 68-75, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26521202

ABSTRACT

The melanocortin-4 receptor (MC4R) is a critical regulator of mammalian food intake and energy expenditure, with receptor activation resulting in decreased food intake and increased energy expenditure. Recently, studies on role of MC4R in regulation of food intake have been extended to other species, such as chicken. Functional study of mutant MC4Rs is important in proving the causal link between MC4R mutation and production traits. Herein, we cloned chicken MC4R (cMC4R) complementary DNA and generated 4 mutant cMC4Rs (Q18H, G21R, S76L, and L299P) by site-directed mutagenesis and measured their expression by flow cytometry. Pharmacologic characteristics were analyzed with binding and signaling assays using 3 agonists. We showed that G21R had decreased cell surface and total expression (P < 0.05), whereas the other 3 mutants had similar total and cell surface expression levels as wild-type cMC4R. The 4 mutants had either decreased (Q18H, G21R, S76L; P < 0.05) or no (L299P) binding to radiolabeled [Nle(4), D-Phe(7)]-α-melanocyte-stimulating hormone (MSH). In signaling assays, Q18H was constitutively active. Q18H, G21R, and S76L had decreased responses to α-MSH stimulation (P < 0.05). L299P had decreased basal and ligand-stimulated signaling (P < 0.01). Nle(4), D-Phe(7)-MSH was the most potent agonist for cMC4R and therefore would be better suited for further in vivo studies. We conclude that the cloned cMC4R was a functional receptor and provided detailed functional data for these mutations, contributing to a better understanding of cMC4R variants associated with production traits.


Subject(s)
Avian Proteins/genetics , Chickens , Mutation , Receptor, Melanocortin, Type 4/genetics , Animals , Avian Proteins/metabolism , Cloning, Molecular , Cyclic AMP/biosynthesis , DNA, Complementary/genetics , Eating/physiology , Energy Metabolism/physiology , Gene Expression , HEK293 Cells , Humans , Mutagenesis, Site-Directed , Receptor, Melanocortin, Type 4/metabolism , Signal Transduction , Transfection , alpha-MSH/pharmacology
7.
Pulm Pharmacol Ther ; 31: 92-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25234924

ABSTRACT

The bronchospasmolytic and secretolytic effects of ivy leaves dry extracts can be explained by an increased ß2-adrenergic responsiveness of the bronchi. Recently, it was shown that α-hederin inhibits the internalization of ß2-adrenergic receptors (ß2AR) under stimulating conditions. α-Hederin pretreated alveolar type II cells and human airway smooth muscle cells revealed an increased ß2AR binding and an elevated intracellular cAMP level, respectively. In order to identify whether additional compounds also mediate an increased ß2-adrenergic responsiveness, we examined the ingredients of an ivy leaves dry extract (EA 575) protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, rutin, kaempferol-3-O-rutinoside, 3,4-, 3,5- and 4,5-dicaffeoylquinic acid, hederacoside B, and ß-hederin. Within all the tested substances, only ß-hederin inhibited the internalization of GFP-tagged ß2AR in stably transfected HEK293 cells. Using fluorescence correlation spectroscopy ß-hederin (1 µM, 24 h) pretreated HASM cells showed a statistically significant increase in the ß2AR binding from 33.0 ± 8.9% to 44.1 ± 11.5% which was distributed with 36.0 ± 9.5% for τbound1 and 8.1 ± 2.6% for τbound2, respectively (n = 8, p < 0.05). The increased binding was selectively found for the receptor-ligand complex with unrestricted lateral mobility (τbound1 of 0.9 ± 0.1 ms, D1 = 9.1 ± 0.2 µm(2)/s, n = 8), whereas the binding of ß2AR with hindered lateral mobility (τbound2 of 64.2 ± 47.6 ms, D2 = 0.15 ± 0.02 µm(2)/s, n = 8) was not affected. Compared to control cells, a statistically significant increase of 17.5 ± 6.4% (n = 4, p < 0.05) and 24.2 ± 5.8% (n = 4, p < 0.001) in the cAMP formation was found for ß-hederin pretreated HASM cells after stimulation with 10 µM of terbutaline and simultaneous stimulation with 10 µM terbutaline and 10 µM forskolin, respectively. Within this systematic study focusing on the influence of the ingredients of an ivy leaves dry extract on HASM cells it was possible to identify ß-hederin as further component presumably responsible for the ß2-mimetic effects.


Subject(s)
Hedera , Myocytes, Smooth Muscle/drug effects , Plant Extracts/pharmacology , Chromatography, High Pressure Liquid , Cyclic AMP/biosynthesis , Dose-Response Relationship, Drug , Flavonoids/pharmacology , HEK293 Cells , Humans , Hydroxybenzoates/pharmacology , Mass Spectrometry , Oleanolic Acid/analogs & derivatives , Oleanolic Acid/pharmacology , Plant Extracts/chemistry , Plant Leaves , Receptors, Adrenergic, beta-2/metabolism , Saponins/pharmacology
8.
Mol Cell Biochem ; 388(1-2): 135-47, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24287564

ABSTRACT

Citrus aurantium extracts, which contain large amounts of p-synephrine, are widely used for weight loss purposes and as appetite suppressants. In the liver, C. aurantium (bitter orange) extracts affect hemodynamics, carbohydrate metabolism, and oxygen uptake. The purpose of the present work was to quantify the action of p-synephrine and also to obtain indications about its mechanism of action, a task that would be difficult to accomplish with C. aurantium extracts due to their rather complex composition. The experimental system was the isolated perfused rat liver. p-Synephrine significantly stimulated glycogenolysis, glycolysis, gluconeogenesis, and oxygen uptake. The compound also increased the portal perfusion pressure and the redox state of the cytosolic NAD(+)/NADH couple. A Ca(2+)-dependency for both the hemodynamic and the metabolic effects of p-synephrine was found. p-Synephrine stimulated both cAMP overflow and the initial Ca(2+) release from the cellular stores previously labeled with (45)Ca(2+). The metabolic and hemodynamic actions of p-synephrine were strongly inhibited by α-adrenergic antagonists and moderately affected by ß-adrenergic antagonists. The results allow to conclude that p-synephrine presents important metabolic and hemodynamic effects in the liver. These effects can be considered as both catabolic (glycogenolysis) and anabolic (gluconeogenesis), they are mediated by both α- and ß-adrenergic signaling, require the simultaneous participation of both Ca(2+) and cAMP, and could be contributing to the overall stimulation of metabolism that usually occurs during weight loss periods.


Subject(s)
Carbohydrate Metabolism/drug effects , Liver/metabolism , Oxygen Consumption/drug effects , Synephrine/pharmacology , Adrenergic alpha-1 Receptor Antagonists/pharmacology , Adrenergic alpha-2 Receptor Antagonists/pharmacology , Adrenergic beta-3 Receptor Antagonists/pharmacology , Animals , Calcium/metabolism , Citrus/metabolism , Cyclic AMP/biosynthesis , Gluconeogenesis/drug effects , Glycogenolysis/drug effects , Glycolysis/drug effects , Male , Oxidation-Reduction/drug effects , Plant Extracts/pharmacology , Prazosin/pharmacology , Propanolamines/pharmacology , Propranolol/pharmacology , Pyruvic Acid/metabolism , Rats , Rats, Wistar , Signal Transduction , Yohimbine/pharmacology
9.
Mol Cell Endocrinol ; 381(1-2): 26-34, 2013 Dec 05.
Article in English | MEDLINE | ID: mdl-23891841

ABSTRACT

Acute in vitro and in vivo biological activities of four novel structural analogues of glucagon were tested. desHis(1)Pro(4)-glucagon, desHis(1)Pro(4)Glu(9)-glucagon, desHis(1)Pro(4)Glu(9)Lys(12)FA-glucagon and desHis(1)Pro(4)Glu(9)Lys(30)FA-glucagon were stable to DPP-4 degradation and dose-dependently inhibited glucagon-mediated cAMP production (p<0.05 to p<0.001). None stimulated insulin secretion in vitro above basal levels, but all inhibited glucagon-induced insulin secretion (p<0.01 to p<0.001). In normal mice all analogues antagonised acute glucagon-mediated elevations of blood glucose (p<0.05 to p<0.001) and blocked corresponding insulinotropic responses. In high-fat fed mice, glucagon-induced increases in plasma insulin (p<0.05 to p<0.001) and glucagon-induced hyperglycaemia were blocked (p<0.05 to p<0.01) by three analogues. In obese diabetic (ob/ob) mice only desHis(1)Pro(4)Glu(9)-glucagon effectively (p<0.05 to p<0.01) inhibited both glucagon-mediated glycaemic and insulinotropic responses. desHis(1)Pro(4)-glucagon and desHis(1)Pro(4)Glu(9)-glucagon were biologically ineffective when administered 8h prior to glucagon, whereas desHis(1)Pro(4)Glu(9)Lys(12)FA-glucagon retained efficacy (p<0.01) for up to 24h. Such peptide-derived glucagon receptor antagonists have potential for type 2 diabetes therapy.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucagon/analogs & derivatives , Glucagon/pharmacology , Hypoglycemic Agents/pharmacology , Receptors, Glucagon/antagonists & inhibitors , Animals , Blood Glucose , Cell Line , Cyclic AMP/biosynthesis , Diabetes Mellitus, Type 2/blood , Dipeptidyl Peptidase 4/chemistry , Drug Evaluation, Preclinical , Glucagon/chemistry , HEK293 Cells , Humans , Insulin/metabolism , Insulin Secretion , Male , Mice , Mice, Obese , Proteolysis
10.
J Ethnopharmacol ; 138(1): 119-25, 2011 Oct 31.
Article in English | MEDLINE | ID: mdl-21925258

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Gastrodia elata (GE) Blume (family Orchidaceae) is a traditional Chinese herbal medicine for treating headaches, dizziness, tetanus, and epilepsy, indicating neuronal protective functions. AIM OF THE STUDY: To evaluate the neuroprotection of GE and its molecular mechanism in preventing serum deprivation-induced PC12 cell apoptosis. MATERIALS AND METHODS: An MTT assay and Hoechst staining were used to respectively validate serum deprivation-induced cell death and apoptosis. Cyclic (c)AMP formation and protein kinase (PK)A activity were also measured after GE treatment. Western blotting was used to detect the phosphorylation of the cAMP response element-binding (CREB) protein. Transient transfection of a dominant negative CREB was used to validate the importance of CREB. RESULTS: GE targeted the adenosine A(2A) receptor (A(2A)-R). GE increased cAMP formation, PKA activity, and phosphorylation of the CREB protein. GE-induced CREB protein phosphorylation and protection was blocked by a PKA inhibitor and overexpression of the dominant negative CREB, respectively. CONCLUSIONS: These results support the neuroprotective effects of GE. The protective mechanism might be mediated through an A(2A)-R/cAMP/PKA/CREB-dependent pathway.


Subject(s)
Adenosine A2 Receptor Agonists/pharmacology , Apoptosis/drug effects , Cyclic AMP Response Element-Binding Protein/metabolism , Gastrodia , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Receptors, Adenosine A2/metabolism , Adenosine A2 Receptor Agonists/isolation & purification , Animals , Cyclic AMP/biosynthesis , Cyclic AMP-Dependent Protein Kinases/metabolism , Gastrodia/chemistry , Neuroprotective Agents/isolation & purification , PC12 Cells , Phosphorylation , Rats
11.
Eur J Pharmacol ; 670(1): 325-32, 2011 Nov 16.
Article in English | MEDLINE | ID: mdl-21914439

ABSTRACT

Considerable evidence shows that chronic hyperglycemia can cause pancreatic beta-cell dysfunction, which contributes to progressive deterioration of glucose homeostasis and overt diabetes. In the present study, we found that kaempferol, a flavonol compound present in various Chinese medicinal herbs, has cytoprotective effects on cultured clonal beta-cells and pancreatic human islets. Kaempferol treatment dose-dependently promoted viability, inhibited cellular apoptosis, and reduced caspase-3 activity in beta-cells and human islets exposed to chronic high glucose, with 10 µM kaempferol exerting the maximum effect. In addition, kaempferol treatment improved the expression of anti-apoptotic proteins Akt and Bcl-2 that was significantly reduced in beta-cells and human islets chronically exposed to hyperglycemia. Furthermore, exposure of beta-cells and human islets to kaempferol restored high glucose-attenuated intracellular cAMP and ATP production. Inhibition of protein kinase A or Akt activation ablated the anti-apoptotic effect of kaempferol. These cytoprotective effects of kaempferol were associated with improved insulin secretory function and synthesis in beta-cells and human islets. These findings provide evidence that kaempferol may be a naturally occurring anti-diabetic compound by protecting pancreatic beta-cell survival and function in a hostile environment that would otherwise lead to type 2 diabetes.


Subject(s)
Hyperglycemia/pathology , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Insulin/metabolism , Kaempferols/pharmacology , Apoptosis/drug effects , Caspase 3/metabolism , Cell Survival/drug effects , Chronic Disease , Cyclic AMP/biosynthesis , Cyclic AMP-Dependent Protein Kinases/metabolism , Gene Expression Regulation/drug effects , Humans , Insulin/biosynthesis , Insulin Secretion , Insulin-Secreting Cells/drug effects , Intracellular Space/drug effects , Intracellular Space/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Signal Transduction/drug effects
12.
J Bone Miner Res ; 26(9): 2096-111, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21638315

ABSTRACT

We recently reported that extracts made from the stem bark of Ulmus wallichiana promoted peak bone mass achievement in growing rats and preserved trabecular bone mass and cortical bone strength in ovariectomized (OVX) rats. Further, 6-C-ß-D-glucopyranosyl-(2S,3S)-(+)-3',4',5,7-tetrahydroxyflavanol (GTDF), a novel flavonol-C-glucoside isolated from the extracts, had a nonestrogenic bone-sparing effect on OVX rats. Here we studied the effects of GTDF on osteoblast function and its mode of action and in vivo osteogenic effect. GTDF stimulated osteoblast proliferation, survival, and differentiation but had no effect on osteoclastic or adipocytic differentiation. In cultured osteoblasts, GTDF transactivated the aryl hydrocarbon receptor (AhR). Activation of AhR mediated the stimulatory effect of GTDF on osteoblast proliferation and differentiation. Furthermore, GTDF stimulated cAMP production, which mediated osteogenic gene expression. GTDF treatments given to 1- to 2-day-old rats or adult rats increased the mRNA levels of AhR target genes in calvaria or bone marrow stromal cells. In growing female rats, GTDF promoted parameters of peak bone accrual in the appendicular skeleton, including increased longitudinal growth, bone mineral density, bone-formation rate (BFR), cortical deposition, and bone strength. GTDF promoted the process of providing newly generated bone to fill drill holes in the femurs of both estrogen-sufficient and -deficient rats. In osteopenic OVX rats, GTDF increased BFR and significantly restored trabecular bone compared with the ovaries-intact group. Together our data suggest that GTDF stimulates osteoblast growth and differentiation via the AhR and promotes modeling-directed bone accrual, accelerates bone healing after injury, and exerts anabolic effects on osteopenic rats likely by a direct stimulatory effect on osteoprogenitors. Based on these preclinical data, clinical evaluation of GTDF as a potential bone anabolic agent is warranted.


Subject(s)
Anabolic Agents/pharmacology , Bone and Bones/pathology , Osteogenesis/drug effects , Osteoporosis/pathology , Quercetin/pharmacology , Receptors, Aryl Hydrocarbon/metabolism , Wound Healing/drug effects , Anabolic Agents/therapeutic use , Animals , Biomechanical Phenomena/drug effects , Body Weight/drug effects , Bone Density/drug effects , Bone Regeneration/drug effects , Bone and Bones/drug effects , Calcification, Physiologic/drug effects , Cyclic AMP/biosynthesis , Female , Hep G2 Cells , Humans , Organ Size/drug effects , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/pathology , Osteoporosis/drug therapy , Plants, Medicinal/chemistry , Quercetin/analogs & derivatives , Quercetin/therapeutic use , Rats , Rats, Sprague-Dawley , Receptors, Aryl Hydrocarbon/genetics , Signal Transduction/drug effects , Transcriptional Activation/drug effects
13.
Urology ; 76(6): 1518.e1-6, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20970829

ABSTRACT

OBJECTIVES: To investigate further the role of phosphodiesterase (PDE) isoenzymes in the control of human seminal vesicle (SV) smooth muscle contractility, we examined the functional responses of isolated SV tissue to various PDE inhibitors. It has been suggested that the application of inhibitors of the PDE type 5 may facilitate SV smooth muscle relaxation and, subsequently, retard ejaculatory response. METHODS: Using the organ bath technique, strip preparations of human SV were exposed for 5 minutes to 1 µM of the PDE inhibitors milrinone (PDE3 inhibitor), rolipram, Ro 20-1724 (PDE4 inhibitors), and sildenafil (PDE5 inhibitor). Norepinephrine (NE, alpha agonist) was then added (0,1 µM, 1 µM, and 10 µM) and isometric responses were recorded. A contraction-response curve to NE in the absence of PDE inhibitors was also generated. Drug effects on the production of cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP) were measured by means of radioimmunometric assays. RESULTS: The contraction induced by NE was effectively antagonized by 1 µM of rolipram (83.3% inhibition), Ro 20-1724 (72.3% inhibition), sildenafil (41.6% inhibition), and milrinone (37.5% inhibition). The inhibition of force generation was paralleled by a 1.6-fold to 2.8-fold increase in tissue cyclic AMP (induced by milrinone, rolipram, Ro 20-1724), and a 12-fold rise in cyclic GMP (induced by sildenafil). CONCLUSION: The findings demonstrate that PDE inhibitors can counteract the contraction of human SV mediated by alpha-adrenergic receptors and enhance levels of cyclic nucleotides. This might be of importance with regard to the identification of new options for the pharmacological treatment of premature ejaculation.


Subject(s)
Cyclic AMP/biosynthesis , Cyclic GMP/biosynthesis , Muscle Relaxation/drug effects , Norepinephrine/antagonists & inhibitors , Phosphodiesterase Inhibitors/pharmacology , Seminal Vesicles/drug effects , 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone/pharmacology , Aged , Colforsin/pharmacology , Drug Evaluation, Preclinical , Ejaculation/drug effects , Humans , In Vitro Techniques , Male , Milrinone/pharmacology , Nitroprusside/pharmacology , Piperazines/pharmacology , Purines/pharmacology , Receptors, Adrenergic, alpha/physiology , Rolipram/pharmacology , Seminal Vesicles/metabolism , Sildenafil Citrate , Sulfones/pharmacology
14.
Eur J Pharmacol ; 623(1-3): 155-9, 2009 Nov 25.
Article in English | MEDLINE | ID: mdl-19766106

ABSTRACT

In a previous work we found that the insecticide 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT), inhibits the accumulation of cAMP as induced by the bovine thyroid stimulating hormone (bTSH) in cells transfected with the TSH receptor. In this work, we demonstrate that the DDT molecular analogues, diethylstilbestrol and quercetine, are more potent inhibitors of the TSH receptor activity than DDT itself. The notion that all these compounds interfere with nuclear estrogen receptors, as either agonists (DDT and diethylstilbestrol) or antagonists (quercetin), prompted us to test the ability of the steroid hormone 17-beta-estradiol to inhibit the TSH receptor activity. We found that estrogen exposure causes a modest but significant inhibition of the bTSH induced cAMP accumulation both in transfected CHO-TSH receptor and Fischer Rat Thyroid Low Serum 5% (FRTL-5) cells. When applied to CHO cells transfected with the luteinizing hormone receptor, 17-beta-estradiol proved capable of inhibiting the hCG induced cAMP accumulation at a concentration as low as 10nM, though the effect was not greater than 35%. The effect of 17-beta-estradiol was not estrogen receptors mediated, as co-transfection of the estrogen receptor alpha and beta subunits with LH receptor caused cAMP to increase above the level attained by the sole hCG stimulation, and not to decrease it as expected. These data suggest the presence of a steroidal-like allosteric binding site on glycoprotein hormone receptors.


Subject(s)
Allosteric Site , DDT/analogs & derivatives , Receptors, Cytoplasmic and Nuclear , Receptors, Thyrotropin/antagonists & inhibitors , Steroids/chemistry , Adenylyl Cyclases/genetics , Animals , CHO Cells , COS Cells , Cell Line , Chlorocebus aethiops , Chorionic Gonadotropin/pharmacology , Cricetinae , Cricetulus , Cyclic AMP/biosynthesis , DDT/pharmacology , Diethylstilbestrol/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Estradiol/pharmacology , Estrogens/pharmacology , Isoenzymes/genetics , Protein Binding , Quercetin/pharmacology , Rats , Rats, Inbred F344 , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Estrogen/genetics , Receptors, LH/genetics , Receptors, Thyrotropin/genetics , Steroids/metabolism , Structure-Activity Relationship , Thyrotropin/pharmacology
15.
J Pharmacol Exp Ther ; 330(3): 810-7, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19491327

ABSTRACT

Studies have shown that long-term (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (morphine) treatment increases the sensitivity to painful heat stimuli (thermal hyperalgesia). The cellular adaptations contributing to sustained morphine-mediated pain sensitization are not fully understood. It was shown previously (J Neurosci 22:6747-6755, 2002) that sustained morphine exposure augments pain neurotransmitter [such as calcitonin gene-related peptide (CGRP)] release in the dorsal horn of the spinal cord in response to the heat-sensing transient receptor potential vanilloid 1 receptor agonist 8-methyl-N-vanillyl-6-nonenamide (capsaicin). In the present study, we demonstrate that sustained morphine-mediated augmentation of CGRP release from isolated primary sensory dorsal root ganglion neurons is dependent on protein kinase A and Raf-1 kinase. Our data indicate that, in addition to neural system adaptations, sustained opioid agonist treatment also produces intracellular compensatory adaptations in primary sensory neurons, leading to augmentation of evoked pain neurotransmitter release from these cells.


Subject(s)
Analgesics, Opioid/pharmacology , Calcitonin Gene-Related Peptide/metabolism , Capsaicin/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Morphine/pharmacology , Proto-Oncogene Proteins c-raf/metabolism , Sensory Receptor Cells/metabolism , Animals , Animals, Newborn , Cell Membrane/drug effects , Cell Membrane/metabolism , Cells, Cultured , Cyclic AMP/biosynthesis , Ganglia, Spinal/cytology , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Indoles/pharmacology , Phenols/pharmacology , Proto-Oncogene Proteins c-raf/antagonists & inhibitors , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Opioid/drug effects , Sensory Receptor Cells/drug effects , TRPV Cation Channels/metabolism
16.
J Obstet Gynaecol Res ; 35(3): 405-13, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19527375

ABSTRACT

OBJECTIVES: The aim of this study was to evaluate the beta-adrenergic receptor (beta-AR) selectivity, organ specificity and efficacy of delaying the onset of spontaneous delivery of bedoradrine (KUR-1246), a novel uterine relaxant. METHODS: beta-AR selectivity was evaluated in terms of the amount of cyclic adenosine monophosphate produced by bedoradrine, ritodrine and isoprenaline in Chinese hamster ovary cells expressing human beta(1)-, beta(2)-AR or beta(3)-AR. Inhibition of contractions of the atrium, trachea and proximal colon by bedoradrine were compared with those of the uterus in pregnant rats using an organ bath method. Finally, the delaying effect of bedoradrine on spontaneous labor was evaluated by an in vivo study using term pregnant rats. RESULTS: EC(50) values of bedoradrine for cyclic adenosine monophosphate production in Chinese hamster ovary cells via beta(1)-, beta(2)- and beta(3)-AR were 2400 +/- 30, 2.9 +/- 0.10 and 363 +/- 3 nmol/L, respectively, indicating that bedoradrine had 832- and 126-fold higher selectivity for beta(2)-AR than for beta(1)- and beta(3)-AR. EC(50) values of bedoradrine for the uterus, atrium, trachea and proximal colon were 1.01 +/- 0.27, 2300 +/- 356, 1610 +/- 299 and 219 +/- 23.5 nmol/L, respectively. Thus, bedoradrine was 2280-, 1590- and 217-fold more specific for the uterus than for the atrium, trachea and proximal colon, respectively. Bedoradrine delayed the spontaneous delivery of 21-day-pregnant rats in a dose-dependent manner. CONCLUSIONS: Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for beta(2)-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery.


Subject(s)
Acetamides/pharmacology , Naphthalenes/pharmacology , Obstetric Labor, Premature/drug therapy , Receptors, Adrenergic, beta-2/drug effects , Tocolytic Agents/pharmacology , Uterus/drug effects , Acetamides/therapeutic use , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclic AMP/biosynthesis , Drug Evaluation, Preclinical , Female , Muscle Contraction/drug effects , Naphthalenes/therapeutic use , Organ Specificity , Pregnancy , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, beta-2/physiology , Tocolytic Agents/therapeutic use , Uterine Contraction/drug effects
17.
J Ethnopharmacol ; 121(1): 43-8, 2009 Jan 12.
Article in English | MEDLINE | ID: mdl-18977427

ABSTRACT

The aim of the study was to investigate the effects of TGP, an active compound extracted from the roots of Paeonia lactiflora Pall, on the activities of synoviocytes in rats with collagen-induced arthritis (CIA) and its possible mechanisms. CIA was induced in male Sprague-Dawley (SD) rats immunized with chicken type II collagen (CII) in Freund's complete adjuvant (FCA). Synoviocytes proliferation was determined by 3-(4, 5-2dimethylthiazal-2yl) 2, 5-diphenyltetrazoliumbromide (MTT) assay. Tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), prostaglandin E(2) (PGE(2)) and cyclic adenosine monophosphate (cAMP) levels in synoviocytes were measured by radioimmunoassay (RIA). E-prostanoid (EP)(2) and EP(4) receptors were analyzed by Western blot analysis. The results showed that TGP significantly inhibited the proliferation of synoviocytes, decreased the production of IL-1, TNF-alpha and PGE(2) and elevated the levels of cAMP. Further study showed that TGP could up-regulate the expression of EP(2) and EP(4). These results indicated that TGP might exert its anti-inflammatory effects through inhibiting the production of pro-inflammatory mediators in synoviocytes of CIA rats, which might be associated with its ability to regulate cAMP-dependent EP(2)/EP(4)-mediated pathway.


Subject(s)
Arthritis, Experimental/drug therapy , Cell Proliferation/drug effects , Glucosides/pharmacology , Glucosides/therapeutic use , Paeonia/chemistry , Phytotherapy , Synovial Membrane/drug effects , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Blotting, Western , Collagen , Cyclic AMP/biosynthesis , Dinoprostone/antagonists & inhibitors , Dinoprostone/metabolism , Drugs, Chinese Herbal/metabolism , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Glucosides/metabolism , Male , Plant Roots/chemistry , Rats , Rats, Sprague-Dawley , Synovial Membrane/metabolism , Synovial Membrane/pathology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism
18.
Int Immunopharmacol ; 8(12): 1658-62, 2008 Dec 10.
Article in English | MEDLINE | ID: mdl-18725324

ABSTRACT

Previously, we and others have demonstrated that wogonin, an active component from the root of Scutellaria baicalensis Georgi, has a neuroprotective effect in cerebral ischemic insult. The neuroprotective effect of wogonin may at least in part be due to its anti-inflammatory properties. Microglial cells, well-known residential macrophages in the central nervous system, migrate to the ischemic lesion and play a pivotal role in the development of chronic inflammation. In the present study, we observed that wogonin potently inhibited microglial migration toward a chemokine, monocyte chemoattractant protein-1 (MCP-1). The anti-migratory effect of wogonin was provoked at nanomolar concentrations, at which wogonin did not significantly inhibit the production of cytokines and chemokines. NF-kappaB has previously shown to regulate microglial cell migration, and activation of cAMP-signaling pathway has also been associated with inhibition of microglial cell motility. In the present study, wogonin at low micromolar concentrations completely suppressed the activity of NF-kappaB in MCP-1-stimulated microglia, and NF-kappaB inhibitors such as N-acetyl cysteine and pyrrolidinedithiocarbamate inhibited the MCP-1-induced migration of microglial cells. However, wogonin did not stimulate the production of cAMP in microglial cells. Our results indicate that the anti-inflammatory activity of wogonin is exerted at least in part by suppressing microglial cell motility via inhibition of NF-kappaB activity.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Flavanones/pharmacology , Microglia/drug effects , NF-kappa B/antagonists & inhibitors , Scutellaria/chemistry , Animals , Cell Movement/drug effects , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL5/antagonists & inhibitors , Cyclic AMP/biosynthesis , Microglia/physiology , Rats , Rats, Sprague-Dawley
19.
Phytomedicine ; 15(12): 1093-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18524559

ABSTRACT

Serotomide (trans-N-caffeoylserotonin) and safflomide (trans-N-caffeoyltryptamine) belong to serotonin-derived phenylpropenoid amides found in plants. In this paper, serotomide and safflomide were investigated to determine their effects on serotonin receptor 5-HT1 in the renal epithelial (OK) cells, due to their structural similarity to 5-HT1 receptor ligands. At the concentration of 10 microM, serotomide was able to inhibit forskolin-stimulated cAMP formation in the OK cells by 31% (p<0.019). The inhibition was repressed by Nan-190 and spiperone (5-HT1 antagonists), suggesting that serotomide suppresses cAMP formation via binding to 5-HT1 receptors in the OK cells. Meanwhile, safflomide could not inhibit forskolin-stimulated cAMP formation at the same concentration (10 microM), but repress the inhibition of forskolin-stimulated cAMP by serotonin agonists (e.g., serotonin and 8-OH-DPAT) by 31% (p<0.018), suggesting that safflomide may block 5-HT1 receptors in a similar way to Nan-190 and spiperone. All together the data indicate that serotomide and safflomide may be potent compounds that respectively act to activate and to block 5-HT1 receptors on OK cells.


Subject(s)
Caffeic Acids/pharmacology , Cyclic AMP/biosynthesis , Serotonin 5-HT1 Receptor Agonists , Serotonin/analogs & derivatives , Tryptamines/pharmacology , Animals , Cell Line , Colforsin/pharmacology , Opossums , Serotonin/pharmacology , Serotonin 5-HT1 Receptor Antagonists , Serotonin Antagonists/pharmacology
20.
Biol Pharm Bull ; 31(4): 583-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18379045

ABSTRACT

Graves' disease, the most common cause of hyperthyroidism, is an autoimmune disorder. Antithyroid drugs have been selected as the first-line treatment of Graves' disease in Korea, Japan, and European countries. However, antithyroid drugs such as methimazole (MMI) and prophylthiouracil (PTU) have limitations in clinical applications because of their side effects. In this study, we performed a clinical trial and in vitro study to investigate the clinical effects and action mechanism of Ahnjeonbaekho-tang (AJBHT), an herbal remedy for Graves' disease. In a clinical study of Graves' disease patients who had side effects from antithyroid drugs, we found that treatment by AJBHT resulted in a reduction of serum triiodothyronine (T3) and free thyroxine (FT4) levels and an increase in thyroid stimulating hormone (TSH) levels (T3: p<0.0001, FT4: p=0.0012, TSH: p=0.0370, respectively). In vitro, AJBHT significantly inhibits FRTL-5 cell proliferation, DNA synthesis, cyclic AMP production, T4 synthesis, and the expression of thyroglobulin (Tg) mRNA in comparison with the control. These results suggest that AJBHT might suppress T(4) synthesis by modulating adenosine 3',5'-cyclic monophosphate (cAMP) and Tg expression, and therefore, AJBHT could be an alternative therapy for Graves' disease patients who have side effects from antithyroid drugs.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Graves Disease/drug therapy , Phytotherapy , Animals , Cell Line , Cell Proliferation/drug effects , Cyclic AMP/biosynthesis , DNA/biosynthesis , Graves Disease/metabolism , Humans , Iodide Peroxidase/biosynthesis , Iodide Peroxidase/blood , Plant Extracts/pharmacology , RNA/biosynthesis , RNA/genetics , Rats , Rats, Inbred F344 , Reverse Transcriptase Polymerase Chain Reaction , Tetrazolium Salts , Thiazoles , Thyroglobulin/biosynthesis , Thyroglobulin/blood , Thyrotropin/biosynthesis , Thyrotropin/blood , Thyroxine/biosynthesis , Thyroxine/blood
SELECTION OF CITATIONS
SEARCH DETAIL